The challenges facing every part of the clinical research ecosystem are having serious adverse effects on patient access to clinical trials. By bringing together key stakeholders to shine a light on the factors that are holding back cancer research, we can find a path forward to solve the issues.
MILWAUKEE (PRWEB)
July 12, 2022
The Society for Immunotherapy of Cancer (SITC) is convening key oncology experts from academia, industry and government, including the FDA and NCI, to lead a national conversation around what’s become a crisis in clinical research – limited patient access to clinical trials and slowed drug development due to staffing shortages, administrative burden, and current business models.
On Aug. 17, 2022, from 10 a.m.–3:30 p.m. ET, SITC will conduct a virtual summit to discuss the key issues impacting cancer clinical trials and severely impacting drug development, future advancements, and most importantly, patient care.
“The challenges facing every part of the clinical research ecosystem are having serious adverse effects on patient access to clinical trials,” said SITC Vice President Leisha Emens, MD, PhD. “By bringing together the key stakeholders to shine a light on the factors that are holding back cancer research, we can find a path forward to solving the issues we are facing.”
The half-day summit will be comprised of presentations from leading experts that detail the crisis, structured panel discussions on the most vexing hurdles facing the field with the opportunity for attendees to be involved through chat functionality. This summit is the first step to resolve the issues facing the advancement of cancer research.
“It’s imperative to the advancement of the science and our patients’ care that we find workable solutions to the current challenges we face,” explained Dr. Emens. “If we don’t, it will set the science back years while our patients still count on us to keep moving forward.”
The summit will be led by a cross-disciplinary set of organizers from all parts of the cancer research landscape. Those individuals are:
- Leisha Emens, MD, PhD – UPMC Hillman Cancer Center
- Marc Ernstoff, MD – National Cancer Institute
- Michael S. Gordon, MD – Honor Health
- David Hong, MD – MD Anderson Cancer Center
- Krystyna Kowalczyk – OncoBay
- Mario Sznol, MD – Yale University
- Stephanie Terzulli, PhD – Memorial Sloan Kettering Cancer Center
- Marc Theoret, MD – US Food and Drug Administration
“The crisis facing clinical research reaches far beyond immunotherapy and oncology,” stated Mary Dean, JD, CAE, SITC’s Executive Director. “As the leading professional organization dedicated to finding a cure to cancer using immunologic approaches, SITC has the leverage and obligation to bring the larger oncology community together to creatively and collaboratively address these hurdles.”
SITC’s Crisis in Clinical Research Virtual Summit is slated for Aug. 17, 2022, from 10 a.m.–3:30 p.m. ET. Please contact policy@sitcancer.org for questions. To learn more, view the schedule and register, please visit sitcancer.org/crisis.
About SITC
Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on Twitter, LinkedIn, Facebook and YouTube.
Share article on social media or email: